Search for: "Shionogi "
Results 1 - 20
of 41
Sort by Relevance
|
Sort by Date
6 Apr 2023, 6:38 am
The judge reviewed the national case law on selections/deletions from multiple lists (Merck v Shionogi [2016] EWHC 2989 (Pat), Nokia v IPCom [2012] EWCA Civ 567 and GlaxoSmithKline v Wyeth [2016] EWHC 1045 (Pat)) and the EPO cases reviewed therein and in the EPO Case Law Book. [read post]
8 Feb 2021, 9:16 am
Readers of the Blog should remember the French landmark French judgment rendered in September 2020 in the European Pemetrexed saga, which condemned Fresenius to pay € 28 million in damages (see here). [read post]
26 Oct 2020, 2:49 am
Joining the majority of European courts, the Paris Court of Justice ruled that Eli Lilly’s patent, which relates to the combined administration of pemetrexed disodium and vitamin B12, was infringed by the marketing of Fresenius’ pemetrexed diacid. [read post]
9 Jul 2020, 9:07 pm
”Biopharmaceutical companies and foundations supporting the fund are:Almirall, Amgen, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, LEO Pharma, Lundbeck, Menarini, Merck, MSD, Novartis, Novo Nordisk, Novo Nordisk Foundation, Pfizer, Roche, Shionogi, Takeda, Teva, and UCBFor more details on the AMR Action Fund, visit www.AMRActionFund.com. [read post]
26 Apr 2018, 10:51 am
Shionogi, 3 Li 1/16 (EP) Today, the German Federal Patent Court published its written reasoning of the 21 November 2017 ruling in the main proceedings of Merck’s compulsory license action. [read post]
17 Oct 2017, 6:09 pm
He noted that the recent litigation between Shionogi v Merck (in which the German Federal Court of Justice confirmed the decision of the Federal Patent Court granting Merck a compulsory license to EP 1 422 218 owned by Shionogi) demonstrated the circumstances where the public interest would support the grant of a compulsory license. [read post]
31 Aug 2017, 10:44 am
Thomas MusmannIn March our partner Hetti Hilge reported on a preliminary injunction by which the Federal Patent Court granted Merck an interlocutory compulsory license for Merck’s HIV drug Isentress in the light of Shionogi’s Raltegravir patent EP 1 422 218 (link). [read post]
12 Jul 2017, 1:00 am
According to its media release of 11 July 2017, the German Federal Court of Justice confirmed the decision of the Federal Patent Court granting Merck a compulsory license to EP 1 422 218 owned by Shionogi. [read post]
9 Mar 2017, 4:41 pm
The patent proprietor, Japanese pharmaceutical company Shionogi, sued Merck in 2015 for patent infringement before the Landgericht Duesseldorf (District Court) and requested an injunction (LG Düsseldorf 4c O 48/15) after the license negotiations between the parties had failed. [read post]
25 Jan 2017, 10:48 pm
Like AIPPI's final talk of 2016, the AmeriKat is alsobristling - but instead of patent law issues, she is bristling having spotted someone wearing socks with sandalsRight before the Christmas holidays, the UK Group of AIPPI held the annual session devoted to reviewing the year's patent cases. [read post]
6 Jan 2017, 2:01 am
| Negative decision for anti-HIV therapy patent: Merck Sharpe & Dohme v Shionogi Co Limited | Book review: Copyright and E-Learning | Friday Fantasies | Fontem see their patent “vaporised” – the dangers of added matter | BREAKING: Antidote found for poisonous priorities | Around the IP blogs | AIPPI Congress Report 5: Antitrust and Pharma - seeking a balance | When the Rolling Stones visited 2120 South Michigan Avenue in Chicago | No measure of success in passing off… [read post]
30 Dec 2016, 2:58 pm
| Negative decision for anti-HIV therapy patent: Merck Sharpe & Dohme v Shionogi Co Limited | Book review: Copyright and E-Learning | Friday Fantasies | Fontem see their patent “vaporised” – the dangers of added matter | BREAKING: Antidote found for poisonous priorities | Around the IP blogs | AIPPI Congress Report 5: Antitrust and Pharma - seeking a balance | When the Rolling Stones visited 2120 South Michigan Avenue in Chicago | No measure of success in passing off… [read post]
22 Dec 2016, 8:35 am
| Negative decision for anti-HIV therapy patent: Merck Sharpe & Dohme v Shionogi Co Limited | Book review: Copyright and E-Learning | Friday Fantasies | Fontem see their patent “vaporised” – the dangers of added matter | BREAKING: Antidote found for poisonous priorities | Around the IP blogs | AIPPI Congress Report 5: Antitrust and Pharma - seeking a balance | When the Rolling Stones visited 2120 South Michigan Avenue in Chicago | No measure of success in passing off… [read post]
16 Dec 2016, 4:44 am
| Negative decision for anti-HIV therapy patent: Merck Sharpe & Dohme v Shionogi Co Limited | Book review: Copyright and E-Learning | Friday Fantasies | Fontem see their patent “vaporised” – the dangers of added matter | BREAKING: Antidote found for poisonous priorities | Around the IP blogs | AIPPI Congress Report 5: Antitrust and Pharma - seeking a balance | When the Rolling Stones visited 2120 South Michigan Avenue in Chicago | No measure of success in passing off… [read post]
9 Dec 2016, 1:00 pm
Eleonora Rosati discusses the VAT Directive comprising the equal treatment for both printed and electronic publications and its implications on digital exhaustion matters.Negative decision for anti-HIV therapy patent: Merck Sharpe & Dohme v Shionogi Co LimitedGuest Kat Eibhlin Vardy recaps Merck Sharp and Dohme Limited v Shionongi & Co Limited, [2016] EWHC 2989 (Pat), involving the alleged infringement of Shionogi’s European Patent, entitled “Antiviral… [read post]
2 Dec 2016, 3:30 am
Data from a total of 104 compounds from Shionogi and 139 from Merck were disclosed. [read post]
11 Apr 2016, 9:25 am
The labeling was in Shionogi & Co. [read post]
1 Mar 2013, 9:53 pm
Image from hereMedicines Patent Pool (MPP) announced the launch of a new collaboration with ViiV Healthcare – a joint venture between GlaxoSmithKline (76.5%), Pfizer (13.5%), and Shionogi (10%) – to facilitate greater availability of critically needed medicines for children living with HIV. [read post]
20 Dec 2012, 12:20 pm
Here, the district court found as fact that Shionogi erred by failing to file an IDS citing the Sandoz and Bayer references, and by omitting a specific claim to the preferred species. [read post]
14 Aug 2012, 9:26 am
(now “Shionogi”) v. [read post]
